Answering patients' needs: oral alternatives to intravenous therapy.
about
Patient-reported preferences for oral versus intravenous administration for the treatment of cancer: a review of the literature.Oral antineoplastic agents: how do we care about adherence?Development of oral immunomodulatory agents in the management of multiple sclerosisImpact of pharmacy channel on adherence to oral oncolytics.Acceptance of oral chemotherapy in breast cancer patients - a survey study.5-Fluorouracil or capecitabine in the treatment of advanced colorectal cancer: a pooled-analysis of randomized trials.Influence of real-world characteristics on outcomes for patients with methicillin-resistant Staphylococcal skin and soft tissue infections: a multi-country medical chart review in EuropeMeta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer.Cost-effectiveness of pazopanib in advanced soft-tissue sarcoma in CanadaSupporting adherence to oral anticancer agents: clinical practice and clues to improve care provided by physicians, nurse practitioners, nurses and pharmacists.The use of capecitabine in daily practice: a study on adherence and patients' experiencesManagement of a locally advanced rectal cancer in a patient who declined surgery.A Systematic Review of Adherence to Oral Antineoplastic TherapiesDo people with cancer comply with oral chemotherapy treatments?A systematic review of economic analyses of pharmaceutical therapies for advanced colorectal cancer.Phase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2+ Breast CancerAdherence and Patients' Experiences with the Use of Capecitabine in Daily Practice.Mind the Gap: Why Closing the Doughnut Hole Is Insufficient for Increasing Medicare Beneficiary Access to Oral ChemotherapyAdherence and patients' experiences with the use of oral anticancer agents.Early-switch/early-discharge opportunities for hospitalized patients with methicillin-resistant Staphylococcus aureus complicated skin and soft tissue infections: proof of concept in the United Arab Emirates.Assessing the need for improved strategies and medication-related education to increase adherence for oral anticancer medications in the young adult oncology population.On glioblastoma and the search for a cure: where do we stand?Re-evaluation of cellular radiosensitization by 5-fluorouracil: high-dose, pulsed administration is effective and preferable to conventional low-dose, chronic administration.Oral vinorelbine in combination with trastuzumab as a first-line therapy of metastatic or locally advanced HER2-positive breast cancer.The Effect of Structured Education to Patients Receiving Oral Agents for Cancer Treatment on Medication Adherence and Self-efficacy.Impact of oral ketamine augmentation on hospital admissions in treatment-resistant depression and PTSD: a retrospective study.Utility values for pre-menopausal women suffering from symptomatic uterine fibroids.Phase I trial of sorafenib in combination with 5-fluorouracil/leucovorin in advanced solid tumors.
P2860
Q27686987-D3EED0C9-B84C-4BDD-B9D5-FB2FE6D2BBDEQ28082909-A4E358EA-A3B6-485F-9A64-3EF5AD2F3988Q28388704-A5CCF959-FD43-4A58-AE5D-8BD6C32BFA49Q33815415-31AC7991-C95D-4424-BCBA-7E8E12F97895Q33870472-F713513A-7DEE-4A6A-A778-A642BCD57AFAQ34180260-EDE92B6D-BA10-4C01-A00B-39214374669FQ34185105-83F225E2-3ADE-449D-957C-E8F552E27884Q34608222-28503A9A-AB8A-4A00-A8B5-6286249C0AF5Q34637866-B955757D-6C31-44EB-93B0-FD6B3C8BE09FQ36277429-2E828773-816E-46B8-B773-0529FE157EB8Q36358178-E3FDE247-6663-49DE-ADDB-606B3003620CQ36498946-4BD09DFE-F7E6-420E-A0AD-E4F81445CE90Q36673490-93801F86-7D31-4D99-A973-B9AE438D6C9CQ36684867-9F494539-3349-4F28-A86D-F71FA842470FQ36847302-D3E48201-672A-4B43-8984-1242B1130C67Q36963374-1A50FDB8-71CC-4D45-BBA5-16AF06F9A06DQ37270640-C78407B0-C077-4540-B87D-C01FC84A18ABQ37350878-96B5BD23-DB0B-4184-B2B2-398171904E93Q38165220-89F9E86A-168C-4A99-AEDC-4609AF300E1DQ38540488-D9469F6F-576F-4D51-A30B-51FEAA58C6E3Q38733672-347C5B07-A978-4E1D-84F7-F0DDBE38AB73Q38756293-C7974BCB-E426-4DC6-81DE-1D28A6F89B90Q39162488-12587554-2FF3-4222-A1C0-3B8DF38ED8FEQ40810672-94CC8164-7F62-4B01-BBE4-F4D1B07A1438Q42138629-49C2F03F-54A0-4CB6-9B12-D392370C6E59Q47213622-8DB515BA-5D7D-43ED-8439-6B884BCC18D7Q48063764-C1EDF6FB-C98D-4045-97C3-CD084191B1E6Q54537291-70CD594D-C4A4-415F-BEDD-A22F4E47FF27
P2860
Answering patients' needs: oral alternatives to intravenous therapy.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Answering patients' needs: oral alternatives to intravenous therapy.
@ast
Answering patients' needs: oral alternatives to intravenous therapy.
@en
Answering patients' needs: oral alternatives to intravenous therapy.
@en-gb
Answering patients' needs: oral alternatives to intravenous therapy.
@nl
type
label
Answering patients' needs: oral alternatives to intravenous therapy.
@ast
Answering patients' needs: oral alternatives to intravenous therapy.
@en
Answering patients' needs: oral alternatives to intravenous therapy.
@en-gb
Answering patients' needs: oral alternatives to intravenous therapy.
@nl
prefLabel
Answering patients' needs: oral alternatives to intravenous therapy.
@ast
Answering patients' needs: oral alternatives to intravenous therapy.
@en
Answering patients' needs: oral alternatives to intravenous therapy.
@en-gb
Answering patients' needs: oral alternatives to intravenous therapy.
@nl
P2093
P1433
P1476
Answering patients' needs: oral alternatives to intravenous therapy.
@en
P2093
P356
10.1634/THEONCOLOGIST.6-SUPPL_4-12
P478
P577
2001-01-01T00:00:00Z